Skip to main content
SpringerLink
Log in

DCE-US: Evaluation of Angiogenesis

  • Chapter
  • First Online:
Functional Imaging in Oncology

  • 1641 Accesses

Abstract

In the era of personalised medicine, imaging indicators of tumour response are needed to guide patient management. Recent technical advances in DCE-US enable measurements of perfusion to quantify the microvascularisation in tumours. Reduction of vascularisation is detectable in responders after 2 weeks treatment and is correlated with progression-free and overall survival in renal and hepatocellular carcinomas. A recent multicentric study of DCE-US (539 patients) demonstrated that the area under the curve is a robust predictor of response at 1 month in several types of body tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AUC:

Area under the curve

AUWI:

Area under the wash-in

AUWO:

Area under the wash-out

DCE-CT:

Dynamic Contrast enhanced Computed Tomography

DCE-MRI:

Dynamic Contrast enhanced Magnetic Resonance Imaging

DCE-US:

Dynamic Contrast enhanced Ultrasonography

EFSUMB:

European Federation of Societies for Ultrasound in Medicine and Biology

ESMO:

European Society for Medical Oncology

FDA:

Food and Drug Administration

GIST:

Gastro-intestinal stromal tumours

HCC:

Hepatocellular carcinomas

mTOR:

Mammalian Target Of Rapamycin

MTT:

Mean transit time

OS:

Overall Survival

PDGF:

Platelet-derived growth factor

PFS:

Progression Free Survival

PI:

Peak intensity

RCC:

Renal cell carcinoma

RECIST 1.1:

Response Evaluation Criteria in Solid Tumours

ROI:

Region of interest

SWI:

Slope of the wash-in

TIC:

Time intensity curve

TKIs:

Tyrosine kinase inhibitors

TPI:

Time to peak intensity

VEGF:

Vascular endothelial growth factor

WFUMB:

The World Federation for Ultrasound in Medicine and Biology

References

  1. Eisenhauer EA, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  PubMed  CAS  Google Scholar 

  2. Rini BI, et al. Renal cell carcinoma. Lancet. 2009;373(9669):1119–32.

    Article  PubMed  CAS  Google Scholar 

  3. Demetri GD. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST. Clin Adv Hematol Oncol. 2009;7(2):S6–7.

    PubMed  Google Scholar 

  4. Motzer RJ. New perspectives on the treatment of metastatic renal cell carcinoma: an introduction and historical overview. Oncologist. 2011;16 Suppl 2:1–3.

    Article  PubMed  Google Scholar 

  5. Reichardt P, Reichardt A. Gastrointestinal stromal tumour (GIST): current standards in multimodal management. Zentralbl Chir. 2011;136(4):359–63.

    Article  PubMed  CAS  Google Scholar 

  6. van der Veldt AA, et al. Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. Br J Cancer. 2010;102(5):803–9.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Albrecht T, et al. Guidelines for the use of contrast agents in ultrasound. January 2004. Ultraschall Med. 2004;25(4):249–56.

    Article  PubMed  CAS  Google Scholar 

  8. Schneider M. Characteristics of SonoVue trade mark. Echocardiography. 1999;16(7 Pt 2):743–6.

    Article  PubMed  Google Scholar 

  9. Cosgrove D. Ultrasound contrast agents: an overview. Eur J Radiol. 2006;60(3):324–30.

    Article  PubMed  Google Scholar 

  10. Cosgrove D, Harvey C. Clinical uses of microbubbles in diagnosis and treatment. Med Biol Eng Comput. 2009;47(8):813–26.

    Article  PubMed  Google Scholar 

  11. Piscaglia F, Bolondi L. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. Ultrasound Med Biol. 2006;32(9):1369–75.

    Article  PubMed  Google Scholar 

  12. Phillips P, Gardner E. Contrast-agent detection and quantification. Eur Radiol. 2004;14 Suppl 8:P4–10.

    PubMed  Google Scholar 

  13. Greis C. Technology overview: SonoVue (Bracco, Milan). Eur Radiol. 2004;14 Suppl 8:P11–5.

    PubMed  Google Scholar 

  14. Lassau N, et al. Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol. 2005;16(7):1054–60.

    Article  PubMed  CAS  Google Scholar 

  15. Lamuraglia M, et al. To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound. Eur J Cancer. 2006;42(15):2472–9.

    Article  PubMed  CAS  Google Scholar 

  16. Escudier B, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresect-able and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res. 2007;13(6):1801–9.

    Google Scholar 

  17. Burns PN, et al. Pulse inversion imaging of liver blood flow: improved method for characterizing focal masses with microbubble contrast. Invest Radiol. 2000;35(1):58–71.

    Article  PubMed  CAS  Google Scholar 

  18. Peronneau P, et al. Contrast ultrasonography: necessity of linear data processing for the quantification of tumor vascularization. Ultraschall Med. 2010;31(4):370–8.

    Article  PubMed  CAS  Google Scholar 

  19. Li PC, Yang MJ. Transfer function analysis of ultrasonic time-intensity measurements. Ultrasound Med Biol. 2003;29(10):1493–500.

    Article  PubMed  Google Scholar 

  20. Goetti R, et al. Quantitative perfusion analysis of malignant liver tumors: dynamic computed tomography and contrast-enhanced ultrasound. Invest Radiol. 2012;47(1):18–24.

    Article  PubMed  Google Scholar 

  21. Cosgrove D, Lassau N. Imaging of perfusion using ultrasound. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S65–85.

    Article  PubMed  Google Scholar 

  22. Lassau N, et al. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res. 2010;16(4):1216–25.

    Article  PubMed  CAS  Google Scholar 

  23. Lassau N, et al. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification – preliminary results. Radiology. 2011;258(1):291–300.

    Article  PubMed  Google Scholar 

  24. Lassau N, et al. Quantitative functional imaging by Dynamic Contrast Enhanced Ultrasonography (DCE-US) in GIST patients treated with masatinib. Invest New Drugs. 2012;30(2):765–71.

    Article  PubMed  CAS  Google Scholar 

  25. Lassau N, et al. Dynamic contrast-enhanced ultrasonography (DCE-US) and anti-angiogenic treatments. Discov Med. 2011;11(56):18–24.

    PubMed  Google Scholar 

  26. Gauthier M, et al. Estimation of intra-operator variability in perfusion parameter measurements using DCE-US. World J Radiol. 2011;3(3):70–81.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Michels J, et al. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma. Invest New Drugs. 2010;28(5):690–3.

    Article  PubMed  Google Scholar 

  28. Lederle W, et al. Imaging in the age of molecular medicine: monitoring of anti-angiogenic treatments. Curr Pharm Biotechnol. 2012;13(4):595–608.

    Article  PubMed  CAS  Google Scholar 

  29. Frampas E, et al. Advanced hepatocellular carcinoma: early Evaluation of response to targeted therapy and prognostic value of perfusion CT and dynamic contrast enhanced-ultrasound. Preliminary results. Eur J Radiol. 2013;82(5):e205–11.

    Article  PubMed  Google Scholar 

  30. Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v98–102.

    Article  PubMed  Google Scholar 

  31. Piscaglia F, et al. The EFSUMB Guidelines and Recommendations on the Clinical Practice of Contrast Enhanced Ultrasound (CEUS): update 2011 on non-hepatic applications. Ultraschall Med. 2012;33(1):33–59.

    Article  PubMed  CAS  Google Scholar 

  32. Claudon M, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver – update 2012: a WFUMB-EFSUMB Initiative in Cooperation with Representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol. 2013;39(2):187–210.

    Article  PubMed  Google Scholar 

  33. Gauthier M, et al. Assessment of quantitative perfusion parameters by dynamic contrast enhanced-ultrasonography using a deconvolution method: an in vitro and in vivo study. J Ultrasound Med. 2012;31(4):595–608.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Department, IRCIV, Institut Gustave-Roussy, Villejuif, France

    Nathalie Lassau MD, PhD

  2. IR4M, UMR8081, Université Paris SUD 11, Institut Gustave-Roussy, 114 avenue Edouard Vaillant, 94805, Villejuif, France

    Nathalie Lassau MD, PhD

Authors
  1. Nathalie Lassau MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nathalie Lassau MD, PhD .

Editor information

Editors and Affiliations

  1. Health Time Group, Jaén, Spain

    Antonio Luna

  2. Dept. of MRI, Clínica Girona, Girona, Spain

    Joan C. Vilanova

  3. Botafogo - Rio de Janeiro/RJ, Brazil

    L. Celso Hygino da Cruz Jr.

  4. Centro de Diagnóstico Dr. Enrique Rossi, Buenos Aires, Argentina

    Santiago E. Rossi

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lassau, N. (2014). DCE-US: Evaluation of Angiogenesis. In: Luna, A., Vilanova, J., Hygino da Cruz Jr., L., Rossi, S. (eds) Functional Imaging in Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40412-2_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-40412-2_17

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-40411-5

  • Online ISBN: 978-3-642-40412-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation